A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007703/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day
respectively
提供机构：
Vivli
创建时间：
2022-02-10
